SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lista S.)
 

Sökning: WFRF:(Lista S.) > (2010-2014) > Perspective on Futu...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004339naa a2200493 4500
001oai:gup.ub.gu.se/188372
003SwePub
008240528s2014 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/1883722 URI
0247 a https://doi.org/10.1016/j.bcp.2013.11.0092 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hampel, Harald4 aut
2451 0a Perspective on Future Role of Biological Markers in Clinical Therapy Trials of Alzheimer's Disease: A Long-Range Point of View Beyond 2020.
264 1b Elsevier BV,c 2014
520 a Recent advances in understanding the molecular mechanisms underlying various paths towards the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
7001 a Lista, Simone4 aut
7001 a Teipel, Stefan J4 aut
7001 a Garaci, Francesco4 aut
7001 a Nisticò, Robert4 aut
7001 a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka
7001 a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe
7001 a Bertram, Lars4 aut
7001 a Duyckaerts, Charles4 aut
7001 a Bakardjian, Hovagim4 aut
7001 a Drzezga, Alexander4 aut
7001 a Colliot, Olivier4 aut
7001 a Epelbaum, Stéphane4 aut
7001 a Broich, Karl4 aut
7001 a Lehéricy, Stéphane4 aut
7001 a Brice, Alexis4 aut
7001 a Khachaturian, Zaven S4 aut
7001 a Aisen, Paul S4 aut
7001 a Dubois, Bruno4 aut
7102 a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
7730 t Biochemical pharmacologyd : Elsevier BVg 88:4, s. 426-449q 88:4<426-449x 1873-2968x 0006-2952
8564 u https://pure.mpg.de/pubman/item/item_1982964_6/component/file_1989744/Hampel.pdf
8564 8u https://gup.ub.gu.se/publication/188372
8564 8u https://doi.org/10.1016/j.bcp.2013.11.009

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy